BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics (GPCR)Structure TherapeuticsEarnings

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026 Aleniglipron Phase 3 initiation expected in 2H 2026

Related news

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

CUECue Biopharma Inc2026-08-14 20:05 EST

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

EQEquillium, Inc.2026-08-13 20:05 EST

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

ELDNEledon Pharmaceuticals, Inc.2026-08-13 20:05 EST

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

STTKShattuck Labs2026-08-11 10:15 EST

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

HCWBHCW Biologics2026-08-14 19:15 EST

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

KYTXKyverna Therapeutics2026-08-11 20:02 EST

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

MREOMereo BioPharma2026-08-11 12:15 EST

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

VERAVera Therapeutics2026-08-10 20:05 EST

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

View all latest news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-06-05 20:05 EST

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Stock data

Close
49.09 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States